Floatz logo

Revumenib

AML, Adult

Center for International Blood and Marrow Transplant ResearchSmall moleculePhase 3Active
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
81/ 100

Competitive context

684 Active assets in the AML, Adult cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB
Posaconazole
AstraZeneca
Phase 4BBB

View all 50 →

Same molecule, other indications

Revumenib is also rated in:

acute myeloid leukemiaDormant
B
Indicative ·
63 / 100
View asset →
acute myeloid leukemia, MLL gene rearrangementDormant
B
Indicative ·
60 / 100
View asset →
mixed phenotype acute leukemiaDormant
B
Indicative ·
59 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →